KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Non-Current Deffered Revenue (2016 - 2017)

Vertex Pharmaceuticals has reported Non-Current Deffered Revenue over the past 9 years, most recently at $1.7 million for Q4 2017.

  • Quarterly results put Non-Current Deffered Revenue at $1.7 million for Q4 2017, down 73.97% from a year ago — trailing twelve months through Dec 2017 was $1.7 million (down 73.97% YoY), and the annual figure for FY2017 was $1.7 million, down 73.97%.
  • Non-Current Deffered Revenue for Q4 2017 was $1.7 million at Vertex Pharmaceuticals, down from $2.9 million in the prior quarter.
  • Over the last five years, Non-Current Deffered Revenue for VRTX hit a ceiling of $90.3 million in Q1 2013 and a floor of $1.7 million in Q4 2017.
  • Median Non-Current Deffered Revenue over the past 5 years was $19.3 million (2015), compared with a mean of $28.1 million.
  • Biggest five-year swings in Non-Current Deffered Revenue: decreased 22.28% in 2013 and later plummeted 73.97% in 2017.
  • Vertex Pharmaceuticals' Non-Current Deffered Revenue stood at $49.5 million in 2013, then plummeted by 43.78% to $27.8 million in 2014, then crashed by 65.07% to $9.7 million in 2015, then crashed by 31.73% to $6.6 million in 2016, then plummeted by 73.97% to $1.7 million in 2017.
  • The last three reported values for Non-Current Deffered Revenue were $1.7 million (Q4 2017), $2.9 million (Q3 2017), and $4.2 million (Q2 2017) per Business Quant data.